OBI Enters License Agreement with Odeon for the Rights of OBI-999 and OBI-833 in China, Hong Kong and Macau

OBI is invited to attend the“ QIC Healthcare Forum” (Investor meeting on air) held by QIC

Announcement of issue price and banks designated to collect and deposit the proceeds

The Active Cancer Immunotherapy OBI-822, has been granted by ANVISA of Brazil to proceed to Phase III Clinical Trial

Supplementary statements on news article

Announcement of preclinical animal study results of OBI’s COVID-19 vaccine

The Active Cancer Immunotherapy OBI-822, has been granted by URPL of Poland to proceed to Phase III Clinical Trial

Announcement of reference date of 2022 cash capital increase and share subscription

The Active Cancer Immunotherapy OBI-822, has been granted by AEMPS of Spain to proceed to Phase III Clinical Trial

The Active Cancer Immunotherapy OBI-822, has been granted by DIGEMID of Peru to proceed to Phase III clinical trial